Prostate Cancer Vaccines
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 30 people enrolled
- Started
- 15 Jun 2025
- Ended
- 31 Jul 2026
- Type of study
- Interventional
- Treatments tested
- Immunomodulatory DC vaccines to target prostate cancer
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Histologically confirmed adenocarcinoma of the prostate
- ECOG performance status 0-1
- Life expectancy ≥ 12 weeks
- WBC ≥ 3,500/µL
- Platelet count ≥ 100,000/µL
- Hemoglobin ≥ 10.0 g/dL
- Creatinine ≤ 2.0 mg/dL
- Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
- AST ≤ 2.5 times ULN
- Fertile patients must use effective contraception
- Willing to provide blood samples for research purposes
- Able to complete questionnaire(s) alone or with assistance
- Able to undergo leukapheresis
- No known immunodeficiency
- No other malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only
- No concurrent serious illness
- No known history of positive PPD skin test
- Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test negative
Who cannot take part
- The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection
- Patients who had previously been treated with cell therapy products and examined by team experts deemed not suitable for treatment
- Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs
- Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products
- Active infection with fever
- Infection with bacteria, fungi or viruses, uncontrolled
- Patients with HIV and those living with active HBV and HCV
- Severe organ failure (heart, liver, kidney, lung)
- Patients with neutropenia (> 10 days) that are difficult to correct after treatment
- Anything that researchers believe may increase the risk of subjects or interfere with test results
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Tumor antigens are protein fragments produced by cancer cells carrying genetic mutations, and many tumor antigens are similar to normal protein antigens, making them unrecognizable by the immune system. Many tumor vaccines are prepared based on a single tumor antigen. This study is based on multiple target antigens using tumor lysates or synthetic peptides. The immune modulation by dendritic-cell (DC)-based cancer vaccines consists of genetically modified DCs to activate T cells to target cancer cells. The study is based on an advanced cancer vaccine technology, which aims to evaluate the safety and potential benefit of the novel immunomodulatory prostate cancer DC vaccines.
The group in the trial
- Experimental: Immunomodulatory DC vaccines to target prostate cancerTreatment being tested
Prostate tumor antigen-modified autologous DCs
Treatment: Immunomodulatory DC vaccines to target prostate cancer
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development of Prostate Cancer Dendritic Cell Vaccines
- Record updated
- 2 November 2026